Publicaciones
-
Mora J, Castañeda-Heredia A, Colombo MC, Gorostegui M, Fernando Gómez Muñoz, Mañe S, Santa-María López V, Garraus-Oneca M, Macias N, Pérez-Jaume S, Muñoz-Aznar O, Muñoz JP, Barber-Martínez de la Torre I and Suñol M.
Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma
Cancers . 13(6): 164. Nº de citas: 7
-
Vega-García N, Pérez-Jaume S, Esperanza-Cebollada E, Vicente-Garces C, Torrebadell-Burriel M, Jiménez-Velasco A, Ortega M, Llop M, Abad L, Vagace JM, Minguela A, Pratcorona M, Sánchez-Garcia J, García-Calderon CB, Gómez-Casares MT, Martín-Clavero E, Escudero A, Riñón M, Muñoz L, Velasco MR, García-Morín M, Català-Temprano A, Pascual A, Velasco P, Fernandez JM, Lassaletta A, Fuster JL, Badell I, Molinos-Quintana A, Molinés A, Guerra-Garcia P, Pérez-Martínez A, García-Abós M, Robles R, Pisa S, Adán R, Díaz de Heredia C, Dapena JL, Rives-Solà S, Ramirez M and Camós-Guijosa M.
Measurable Residual Disease Assessed by Flow-Cytometry Is a Stable Prognostic Factor for Pediatric T-Cell Acute Lymphoblastic Leukemia in Consecutive SEHOP Protocols Whereas the Impact of Oncogenetics Depends on Treatment.
Frontiers in pediatrics . 8: 614521-614521. Nº de citas: 5
-
Mora J, Castañeda-Heredia A, Flores MA, Santa-María V, Garraus-Oneca M, Gorostegui M, Simao M, Pérez-Jaume S and Mañe S.
The Role of Autologous Stem-Cell Transplantation in High-Risk Neuroblastoma Consolidated by anti-GD2 Immunotherapy. Results of Two Consecutive Studies
FRONTIERS IN PHARMACOLOGY . 11: 575009-575009. Nº de citas: 15
-
Castillo H, Monterrubio C, Pascual-Pastó G, Gomez-Gonzalez S, Garcia-Dominguez DJ, Hontecillas-Prieto L, Resa-Parés C, Burgeño-Sandoval V, Paco-Mercader S, Gene-Olaciregui N, Vilà-Ubach M, Restrepo-Perdomo C, Cuadrado-Vilanova M, Balaguer-Lluna L, Pérez-Jaume S, Castañeda-Heredia A, Santa-María López V, Roldan-Molina M, Suñol M, de Alava E, Mora J, Lavarino C and Carcaboso AM.
Treatment-driven selection of chemoresistant Ewing sarcoma tumors with limited drug distribution
JOURNAL OF CONTROLLED RELEASE . 324: 440-449. Nº de citas: 6
-
Garcia-López M, Rodriguez-Hernandez CJ, Mateo-Lozano S, Pérez-Jaume S, Gonçalves-Alves E, Lavarino C, Mora J and de Torres C.
Parathyroid hormone-like hormone plays a dual role in neuroblastoma depending on PTH1R expression
MOLECULAR ONCOLOGY . 13(9): 1959-1975. Nº de citas: 8
-
Vega-García N, Malatesta R, Estella-Aguado MC, Pérez-Jaume S, Esperanza-Cebollada E, Torrebadell-Burriel M, Català-Temprano A, Gassiot S, Berrueco R, Ruiz-Llobet A, Alonso-Saladrigues A, Mesegue-Meda M, Pont-Martí S, Rives-Solà S and Camós-Guijosa M.
Paediatric patients with acute leukaemia and KMT2A (MLL) rearrangement show a distinctive expression pattern of histone deacetylases
BRITISH JOURNAL OF HAEMATOLOGY . 182(4): 542-553. Nº de citas: 7
-
Mora J, Pérez-Jaume S and Cruz-Martínez O.
Treatment of childhood astrocytomas with irinotecan and cisplatin
CLINICAL & TRANSLATIONAL ONCOLOGY . 20(4): 500-507. Nº de citas: 3
-
Gomez-Gonzalez S, Garrido- García A, García-Gerique L, Lemos I, Suñol M, de Torres C, Kulis M, Pérez-Jaume S, Carcaboso AM, Luu B, Kieran MW, Jabado N, Kozlenkov A, Dracheva S, Ramaswamy V, Hovestadt V, Johann P, Jones DTW, Pfister SM, Morales-La Madrid A, Cruz-Martínez O, Taylor MD, Martín-Subero JI, Mora J and Lavarino C.
A Novel Method for Rapid Molecular Subgrouping of Medulloblastoma
CLINICAL CANCER RESEARCH . 24(6): 1355-1363. Nº de citas: 22
-
Pérez-Jaume S, Skaltsa K, Pallarès N and Carrasco JL.
ThresholdROC: Optimum Threshold Estimation Tools for Continuous Diagnostic Tests in R
Journal of Statistical Software . 82(4): 1-21. Nº de citas: 20
-
Mora J, Castañeda A, Pérez-Jaume S, Lopez-Pousa A, Maradiegue E, Valverde C, Martin-Broto J, Garcia Del Muro X, Cruz-Martínez O, Cruz J, Martinez-Trufero J, Maurel J, Vaz MA, de Alava E and de Torres C.
GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS)
BRITISH JOURNAL OF CANCER . 117(6): 767-774. Nº de citas: 15